Skip to main content
. 2020 Jan 14;295(8):2495–2505. doi: 10.1074/jbc.REV119.007759

Figure 3.

Figure 3.

Different drug discovery approaches to targeting integrin for cancer therapy. A, conjugate presenting a selective binder for the extracellular region of integrin aVb3 (black) covalently linked to sunitinib (blue) (79). B, amphiphilic dendrimer composed with a dual-targeting peptide bearing an Arg-Gly-Asp-Lys (RGDK) lipopeptide (red) (C) (81). D, atorvastatin identified as a novel candidate for drug repurposing for undruggable integrins (82).